Nektar Therapeutics
NKTR
$75.06
$2.853.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 55.23M | 62.60M | 74.93M | 87.25M | 98.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 55.23M | 62.60M | 74.93M | 87.25M | 98.43M |
| Cost of Revenue | -- | 7.98M | 12.41M | 22.15M | 30.69M |
| Gross Profit | 55.23M | 54.62M | 62.52M | 65.10M | 67.74M |
| SG&A Expenses | 68.67M | 74.62M | 77.51M | 80.95M | 76.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 186.00M | 198.96M | 214.06M | 227.08M | 228.35M |
| Operating Income | -130.77M | -136.36M | -139.13M | -139.83M | -129.92M |
| Income Before Tax | -164.21M | -121.16M | -122.66M | -133.19M | -119.20M |
| Income Tax Expenses | -138.00K | -428.00K | -386.00K | -152.00K | -239.00K |
| Earnings from Continuing Operations | -164.08 | -120.74 | -122.27 | -133.04 | -118.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -164.08M | -120.74M | -122.27M | -133.04M | -118.96M |
| EBIT | -130.77M | -136.36M | -139.13M | -139.83M | -129.92M |
| EBITDA | -129.75M | -135.20M | -137.17M | -136.62M | -125.53M |
| EPS Basic | -10.22 | -7.93 | -8.71 | -9.52 | -8.73 |
| Normalized Basic EPS | -6.10 | -6.69 | -7.17 | -7.09 | -6.57 |
| EPS Diluted | -10.22 | -7.94 | -8.72 | -9.53 | -8.74 |
| Normalized Diluted EPS | -6.10 | -6.66 | -7.15 | -7.07 | -6.54 |
| Average Basic Shares Outstanding | 67.39M | 61.08M | 56.08M | 55.92M | 54.84M |
| Average Diluted Shares Outstanding | 67.39M | 61.34M | 56.34M | 56.17M | 55.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |